C-reactive protein in Crohn's disease: How informative is it?

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 4, 2014, Pages 393-408

  Magro, Fernando ^a,b,c,d   Sousa, Paula ^e   Ministro, Paula ^e  

^a University of Porto   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e Centro Hospitalar Tondela Viseu   (Portugal)

Author keywords

anti TNF; biomarkers; C reactive protein; clinical activity indices; Crohns disease; differential diagnosis; endoscopic indices of activity; outcome

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CALGRANULIN; CERTOLIZUMAB PEGOL; FC RECEPTOR; LACTOFERRIN; NATALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; BIOLOGICAL MARKER;

ADIPOCYTE; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL (TOPIC); CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIGESTIVE TRACT ENDOSCOPY; DOSAGE SCHEDULE COMPARISON; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; GENOTYPE ENVIRONMENT INTERACTION; HEALING; HISTOPATHOLOGY; HUMAN; LIFESTYLE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHAGOCYTOSIS; PHENOTYPE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RECEPTOR BINDING; REVIEW; SENSITIVITY AND SPECIFICITY; SOCIOECONOMICS; TREATMENT RESPONSE; ULCERATIVE COLITIS; ACUTE PHASE RESPONSE; IMMUNOLOGY; METABOLISM; PREDICTIVE VALUE;

ACUTE-PHASE REACTION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; PREDICTIVE VALUE OF TESTS;

EID: 84898965761     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.893821     Document Type: Review

References (97)

1. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930;52(4):561-71
2. Abernethy TJ, Avery OT. The occurrence during acute infections of a protein not normally present in the blood: I. Distribution of the reactive protein in patient's sera and the effect of calcium on the flocculation reaction with C polysaccharide of pneumococcus. J Exp Med 1941;73(2):173-82
3. Macleod CM, Avery OT. The occurrence during acute infections of a protein not normally present in the blood: II. Isolation and properties of the reactive protein. J Exp Med 1941;73(2):183-90
4. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999;7(2):169-77 (Pubitemid 29159702)
5. Du Clos TW. Pentraxins: structure, function, and role in inflammation. ISRN Inflamm 2013;2013:379040
6. Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein formation. J Exp Med 1966;123(2):365-78
7. Ablij H, Meinders A. C-reactive protein: history and revival. Eur J Intern Med 2002; 13(7):412
8. Rhodes B, Furnrohr BG, Vyse TJ. C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol 2011; 7(5):282-9
9. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10(5):661-5 (Pubitemid 39276479)
10. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001;38(2-3):189-97 (Pubitemid 32786776)
11. Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut 2012; 61(1):78-85
12. Peisajovich A, Marnell L, Mold C, Du Clos TW. C-reactive protein at the interface between innate immunity and inflammation. Exp Rev Clin Immunol 2008;4(3):379-90 (Pubitemid 351903275)
13. Pankow JS, Folsom AR, Cushman M, et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001;154(3):681-9 (Pubitemid 32232166)
14. Rhodes B, Merriman ME, Harrison A, et al. A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation. PLoS Med 2010;7(9): e1000341
15. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol (Orlando, Fla) 2005;117(2):104-11 (Pubitemid 41407719)
16. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999;42(1-3):23-30 (Pubitemid 29322284)
17. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55(3):426-31 (Pubitemid 43268284)
18. Dubinsky M. What is the role of serological markers in IBD? Pediatric and adult data. Dig Dis (Basel, Switzerland) 2009;27(3): 259-68
19. Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008;14(1): 32-9 (Pubitemid 351196866)
20. Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995;73(4):354-5
21. Ricanek P, Brackmann S, Perminow G, et al. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol 2011;46(9):1081-91
22. Shine B, Berghouse L, Jones JE, Landon J. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 1985;148(2):105-9 (Pubitemid 15034646)
23. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002;14(4):409-12 (Pubitemid 34439041)
24. Tsampalieros A, Griffiths AM, Barrowman N, Mack DR. Use of C-reactive protein in children with newly diagnosed inflammatory bowel disease. J Pediatr 2011; 159(2):340-2
25. Campbell CA, Walker-Smith JA, Hindocha P, Adinolfi M. Acute phase proteins in chronic inflammatory bowel disease in childhood. J Pediatr Gastroenterol Nutr 1982;1(2):193-200 (Pubitemid 12013433)
26. Schoepfer AM, Trummler M, Seeholzer P, et al. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 2007;50(10):1697-706 (Pubitemid 47583348)
27. Erbayrak M, Turkay C, Eraslan E, et al. The role of fecal calprotectin in investigating inflammatory bowel diseases. Clinics (Sao Paulo) 2009;64(5):421-5
28. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103(1):162-9
29. Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986;27(7):809-13 (Pubitemid 16058500)
30. Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol 2006;41(3):306-11
31. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008;57(11): 1518-23
32. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014;63(1):88-95
33. Kiss LS, Papp M, Lovasz BD, et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification? Inflamm Bowel Dis 2012;18(9):1647-54
34. Buckell NA, Lennard-Jones JE, Hernandez MA, et al. Measurement of serum proteins during attacks of ulcerative colitis as a guide to patient management. Gut 1979;20(1):22-7 (Pubitemid 9120965)
35. Prantera C, Davoli M, Lorenzetti R, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988;10(1):41-5 (Pubitemid 18062520)
36. Zilberman L, Maharshak N, Arbel Y, et al. Correlated expression of high-sensitivity Creactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. Digestion 2006;73(4): 205-9 (Pubitemid 44448880)
37. Sidoroff M, Karikoski R, Raivio T, et al. High-sensitivity C-reactive protein in paediatric inflammatory bowel disease. World J Gastroenterol 2010;16(23):2901-6
38. Mazlam MZ, Hodgson HJ. Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut 1994;35(1):77-83
39. Vermeire S, Assche GV, Rutgeerts P. Role of biomarkers in the diagnosis of inflammatory bowel disease. Expert Opin Med Diagn 2007;1(4):481-8
40. Gross V, Andus T, Caesar I, et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992;102(2):514-19
41. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, et al. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut 2007;56(4):577-83 (Pubitemid 46580516)
42. Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007; 52(9):2063-8 (Pubitemid 47246515)
43. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105(1):162-9
44. Chamouard P, Richert Z, Meyer N, et al. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 2006;4(7):882-7 (Pubitemid 43994532)
45. Kellermayer R, Mir SA, Nagy-Szakal D, et al. Microbiota separation and C-reactive protein elevation in treatment-naive pediatric granulomatous Crohn disease. J Pediatr Gastroenterol Nutr 2012;55(3): 243-50
46. Andre C, Descos L, Landais P, Fermanian J. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut 1981;22(7):571-4 (Pubitemid 11053344)
47. Karoui S, Ouerdiane S, Serghini M, et al. Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. Dig Liver Dis 2007;39(11):1006-10 (Pubitemid 350018697)
48. Tilakaratne S, Lemberg DA, Leach ST, Day AS. C-reactive protein and disease activity in children with Crohn's disease. Dig Dis Sci 2010;55(1):131-6
49. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6(11):1218-24
50. Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis 2007;13(9):1100-5 (Pubitemid 47402593)
51. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11(8): 707-12 (Pubitemid 41271173)
52. Filik L, Dagli U, Ulker A. C-reactive protein and monitoring the activity of Crohn's disease. Adv Ther 2006;23(4): 655-62 (Pubitemid 44747446)
53. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases Inflamm Bowel Dis. 2007;13(12):1545-53
54. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340(6): 448-54 (Pubitemid 29084777)
55. Tromm A, Tromm CD, Huppe D, et al. Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease. Scand J Gastroenterol 1992;27(9):774-8
56. Meuwis MA, Vernier-Massouille G, Grimaud JC, et al. Serum calprotectin as a biomarker for Crohn's disease. J Crohns Colitis 2013;7(12):e678-83
57. Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes 2009;2:221
58. Dolwani S, Metzner M, Wassell JJ, et al. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004;20(6):615-21 (Pubitemid 39279049)
59. Eder P, Stawczyk-Eder K, Krela-Kazmierczak I, Linke K. Clinical utility of the assessment of fecal calprotectin in Lesniowski-Crohn's disease. Pol Arch Med Wewn 2008;118(11):622-6
60. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14(1):40-6 (Pubitemid 351196867)
61. Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 2009;96(6):663-74
62. Minderhoud IM, Samsom M, Oldenburg B. What predicts mucosal inflammation in Crohn's disease patients? Inflamm Bowel Dis 2007;13(12):1567-72
63. Daperno M, Castiglione F, de Ridder L, et al. Results of the 2nd part Scientific Workshop of the ECCO. II: measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis 2011;5(5): 484-98
64. Gomes P, du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986;27(1):92-5 (Pubitemid 16134482)
65. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The groupe d'etudes therapeutiques des affections inflammatoires digestives. Gut 1994;35(2):231-5 (Pubitemid 24092870)
66. Colombel JF, Solem CA, Sandborn WJ, et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 2006;55(11):1561-7 (Pubitemid 44629202)
67. Moran A, Jones A, Asquith P. Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn's colitis. Scand J Gastroenterol 1995;30(4):356-60
68. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140(6):1817-26; e2
69. Lee SS, Ha HK, Yang SK, et al. CT of prominent pericolic or perienteric vasculature in patients with Crohn's disease: correlation with clinical disease activity and findings on barium studies. AJR Am J Roentgenol 2002;179(4):1029-36
70. Sauer CG, Middleton JP, Alazraki A, et al. Comparison of magnetic resonance enterography with endoscopy, histopathology, and laboratory evaluation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012;55(2):178-84
71. Maccioni F, Viscido A, Broglia L, et al. Evaluation of Crohn disease activity with magnetic resonance imaging. Abdom Imaging 2000;25(3):219-28 (Pubitemid 30304973)
72. Kushner I. C-reactive protein and the acute-phase response. Hospital practice (Office ed) 1990;25(3a):13, 6, 21-8
73. Tall AR. C-reactive protein reassessed. N Engl J Med 2004;350(14):1450-2 (Pubitemid 38420000)
74. Vermeire S, Van Assche G, Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005;2(12):580-6
75. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988;10(4):401-5
76. Reinisch W, Wang Y, Oddens BJ, Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012;35(5):568-76
77. Jurgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011;9(5):421-7; e1
78. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002;37(7):818-24 (Pubitemid 34836819)
79. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362(15):1383-95
80. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130(2):323-33; quiz 591
81. Sandborn WJ, Colombel JF, D'Haens G, et al. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease. Curr Med Res Opin 2013;29(5): 483-93
82. Kiss LS, Szamosi T, Molnar T, et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011;34(8):911-22
83. De Cruz P, Kamm MA, Prideaux L, et al. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis 2013;19(2):429-44
84. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012;142(5):1102-11; e2
85. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142(2):257-65; e1-3
86. Magro F, Rodrigues-Pinto E, Santos-Antunes J, et al. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis 2014;8(2):129-36
87. Lewis JD. C-reactive protein: anti-placebo or predictor of response. Gastroenterology 2005;129(3):1114-16 (Pubitemid 41242700)
88. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129(3):807-18 (Pubitemid 41242673)
89. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353(18):1912-25 (Pubitemid 41565956)
90. Toedter GP, Blank M, Lang Y, et al. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol 2009;104(11):2768-73
91. Consigny Y, Modigliani R, Colombel JF, et al. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006; 12(7):551-7 (Pubitemid 43977735)
92. Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008;14(1): 85-9 (Pubitemid 351314332)
93. Bitton A, Dobkin PL, Edwardes MD, et al. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 2008;57(10): 1386-92
94. Lakatos PL, Kiss LS, Palatka K, et al. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflamm Bowel Dis 2011;17(3):767-77
95. Image from the RCSB PDB of PDB ID 1B09. Thompson D, Pepys MB, Wood SP, The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure (London, England: 1993) 1999.7(2):169-77. Available from: www.rcsb.org
96. Cabrera-Abreu JC, Davies P, Matek Z, Murphy MS. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 2004;89(1): 69-71 (Pubitemid 38122017)
97. Faubion WA Jr, Fletcher JG, O'Byrne S, et al. Emerging biomarkers in inflammatory bowel disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol 2013;108(12):1891-900